First- and second-line treatments used to treat cutaneous leishmaniasis
| Treatment | No. (%) of patients who received first-line treatment | No. (%) of patients who received second-line treatment | ||||
|---|---|---|---|---|---|---|
| Total n = 47 | Old World exposure n = 15 | New World exposure n = 32 | Total n = 16 | Old World exposure n = 8 | New World exposure n = 8 | |
| Local | 2 (4) | 2 (13) | 0 (0) | 4 (25) | 3 (38) | 1 (12) |
| Systemic | 36 (77) | 12 (80) | 24 (75) | 9 (56) | 3 (38) | 6 (75) |
| No treatment | 9 (19) | 1 (7) | 8 (25) | 3 (19) | 2 (25) | 1 (12) |
| Specific treatment* | 38 (81) | 14 (93) | 24 (75) | 13 (81) | 6 (75) | 7 (88) |
| Liposomal amphotericin B | 20 (53) | 4 (29) | 16 (67) | 4 (31) | 1 (17) | 3 (43) |
| Oral fluconazole | 10 (26) | 5 (36) | 5 (21) | 3 (23) | 1 (17) | 2 (29) |
| IV pentavalent antimonial | 4 (11) | 3 (21) | 1 (4) | 2 (15) | 1 (17) | 1 (14) |
| Topical paromomycin | 1 (2.5) | 1 (7) | 0 (0) | 2 (15) | 1 (17) | 1 (14) |
| Pentamidine | 1 (2.5) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) |
| Topical paromomycin with fluconazole | 1 (2.5) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) |
| IL pentavalent antimonial | 1 (2.5) | 1 (7) | 0 (0) | 1 (8) | 1 (17) | 0 (0) |
| Cryotherapy | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 1 (17) | 0 (0) |
Note: IL = intralesional, IV = intravenous.
↵* Percent frequencies are a proportion of all patients who received a specific treatment.